Is Ozempic the same as Wegovy?

They contain the same molecule, semaglutide, made by the same manufacturer, but they are marketed as separate branded prescription drugs for different approved uses and at different studied doses. The active ingredient is identical; the label, indication, and dosing schedule differ.

Is semaglutide just the generic name for Ozempic and Wegovy?

Semaglutide is the name of the molecule; Ozempic and Wegovy are two brand names for that molecule as an FDA-approved prescription drug. Separately, semaglutide is also sold as a research chemical for laboratory use — that research-grade version is not the branded drug and is not FDA-approved.

Is research-grade semaglutide the same as Ozempic or Wegovy?

No. Research-grade semaglutide sold "for research use only" is a different product from the branded prescription drugs. It is not FDA-approved, is not made to a pharmaceutical standard, and no one verifies its purity or content. See /peptides/semaglutide for the honest status.

Why do Ozempic and Wegovy have different doses if they are the same drug?

Because they were studied and approved for different uses. The diabetes brand and the weight-management brand were tested at different target doses in separate trial programs, so each label reflects the dose and population its own studies used.

GLP-1

Ozempic vs Wegovy vs Semaglutide: One Molecule, Two Brands, and the Research-Grade Version Explained

By MrPepTalks Editorial · Updated 2026-07-08

People search "Ozempic vs Wegovy vs semaglutide" as if they were three competing products, and the honest answer surprises almost everyone: they are not three different things. Ozempic and Wegovy are two brand names for the very same molecule, semaglutide, sold by the same manufacturer under different labels and different approved uses. "Semaglutide" is the molecule itself. This guide is a plain-English decoder for the name confusion: what is actually the same, what is genuinely different, and why the research-grade semaglutide sold online is a separate matter from either branded drug.

The one thing to understand: it is a single molecule

Semaglutide is a GLP-1 receptor agonist, a lab-made peptide that mimics a natural gut hormone the body releases after eating. That is the compound. Ozempic and Wegovy are brand names a pharmaceutical company gives to that compound when it packages and markets it for a specific approved use. The molecule inside does not change between the two brands; what changes is the label, the marketed indication, and the dosing schedule the manufacturer studied and submitted. So the real relationship is not "A vs B vs C" — it is one compound (semaglutide) wearing two different brand jackets (Ozempic and Wegovy), plus a third, entirely separate track: the research-grade powder sold for laboratory use.

What Ozempic is

Ozempic is the brand name for semaglutide as the FDA-approved prescription drug indicated for type 2 diabetes; a related lower-dose oral form is sold under a different brand. In its trial program, once-weekly semaglutide was studied for blood-sugar control and, in a large cardiovascular outcomes study, for the risk of heart-related events in adults with type 2 diabetes. Ozempic is the name you will most often hear in a diabetes context. It is a real, human-tested, prescription-only medicine — which is exactly what the research-grade powder is not: the material sold for lab use is not the branded Ozempic product and is not FDA-approved.

What Wegovy is

Wegovy is the brand name for semaglutide as the FDA-approved prescription drug for chronic weight management, given at a higher target dose than the diabetes brand. In the STEP 1 trial, the study reported that adults with overweight or obesity who received once-weekly semaglutide plus lifestyle support had a mean body-weight reduction of about 15% over 68 weeks, compared with about 2.6% on placebo. A separate cardiovascular outcomes study, SELECT, reported a lower rate of major adverse cardiovascular events in adults with established heart disease and overweight or obesity without diabetes. Same molecule as Ozempic; different brand, different approved indication, different studied dose. As with the diabetes brand, the research-grade semaglutide powder sold for lab use is not the branded Wegovy product and is not FDA-approved.

Why one molecule has two brand names

Regulators approve a drug for a specific use, backed by trials designed for that use. When a manufacturer runs one trial program for blood-sugar control and a separate one for weight management, it commonly markets the results under two brand names so each label reflects the population and dose that were actually studied. That is why the same semaglutide appears as one brand for diabetes and another for weight management. It is a labeling and marketing distinction layered on top of an identical active ingredient — not a chemical difference between the products.

The research-grade semaglutide sold online is a different matter

Here is the part the brand-vs-brand framing hides. The semaglutide sold as a research chemical — labeled "for research use only, not for human consumption" — is not Ozempic and it is not Wegovy. It is not the FDA-approved branded product, and research-grade semaglutide sold for lab use is not FDA-approved. It has not been manufactured, tested, or released to a pharmaceutical standard, so no one verifies its purity, its sterility, or what the vial actually contains. Independent testing of gray-market peptide supply has repeatedly turned up mislabeled, underdosed, overdosed, or contaminated products. The molecule may be nominally the same as what is inside the branded drugs, but the product, the oversight, and the safety assurances are not. Treat the research-grade version as its own honest question, covered on our data-sheet at /peptides/semaglutide and our full verdict at /verdicts/semaglutide.

Cons and reported side effects

None of this is free of downsides, and an honest decoder has to say so. Across the branded semaglutide trials, the most commonly reported side effects were gastrointestinal — nausea, vomiting, diarrhea, and constipation — which led some participants to stop treatment. Studies have also examined gallbladder-related events and other effects, and the branded products carry manufacturer warnings that a prescriber reviews. Weight and blood-sugar changes seen in trials were not uniform, and for many people the changes faded after stopping. For the research-grade version the picture is worse, not better: without pharmaceutical manufacturing or a prescriber, you inherit all of those reported side effects plus the supply-quality and mislabeling risks above, with no medical oversight. Benefits belong next to the caveats, always.

How this compares to the other GLP-1 names you see

Semaglutide is not the only molecule in this crowded naming space, which adds to the confusion. Tirzepatide is a different molecule — a dual GLP-1 and GIP receptor agonist — sold under its own branded prescription drugs, and it is commonly researched alongside semaglutide because both are studied for metabolic outcomes. If you are trying to sort out which molecule is which, our head-to-head explainer at /compare/tirzepatide-vs-semaglutide walks through how the two differ on mechanism, class, and what the research has and has not shown, and the tirzepatide data-sheet lives at /peptides/tirzepatide.